18 July 2025 in Science Advances
C-peptide is a critical biomarker for evaluating pancreatic β cell function and managing diabetes. However, conventional methods such as enzyme-linked immunosorbent assay are limited by lengthy processing times and the necessity for invasive sample collection. This study introduces a regenerable, portable, and wearable device for minimally invasive, real-time monitoring of C-peptide in dermal interstitial fluid (ISF). The device uses a microneedle array and negative pressure extraction for ISF collection. A double-antibody sandwich approach was used to detect C-peptide, and an antibody regeneration strategy was applied to remove bound antigen-antibody complexes, thereby achieving repeatable detection, enabling at least 10 detection assays on the same chip with negligible signal attenuation. The compact design features a skin contact area of only 3 cm by 5.4 cm and excellent biocompatibility. Integrated with a mobile app, the device provides real-time concentration reading. Mouse and rabbit tests confirm effective ISF sampling and monitoring accuracy, demonstrating its potential for at-home diabetes management and broader wearable biosensing applications.
24 October 2025 in Science Advances
No clinically available antibiotic adjuvants can overcome metallo-β-lactamase (MBL) resistance in carbapenem-resistant Gram-negative ESKAPE pathogens. Divalent cations in MBL and quasicrystalline lipopolysaccharides (LPS) are key determinants of acquired and intrinsic resistance in these bacteria. Chemically depriving these cations would block multiple resistance pathways simultaneously and restore carbapenem susceptibility. Here, we chemically engineer a class of anionic adjuvants to tailor their interactions with MBL, enhancing the enzymatic inhibition by up to ~5885-fold compared to parent compounds. An orthogonal screen identifies the tiopronin-engineered anionic adjuvant (TINA), which achieves complete rescue of all tested carbapenems against diverse New Delhi metallo-β-lactamase-1–producing Gram-negative ESKAPE bacteria. TINA targets both MBL and LPS, depriving divalent cations to inactivate MBL and damage membrane collaboratively while also preventing resistance evolution. Moreover, TINA’s anionic nature minimizes serum adsorption, enabling safe and effective in vivo treatment of bacterial pneumonia. This work provides an innovative chemical biology strategy leveraging anionic materials to combat superbugs globally.
19 May 2026 in Sensors and Actuators B: Chemical
12 March 2026 in SSRN Electronic Journal
Iodine contrast media (ICM) are extensively applied in diagnostic and interventional imaging, yet hypersensitivity reactions associated with their use remain a major clinical challenge due to their unpredictability and potential severity. Despite the clinical importance, there are currently no serum-based diagnostic methods or mechanistic studies that allow reliable identification of patients with ICM hypersensitivity. In this work, we report a label-free biosensing strategy for discriminating against ICM-hypersensitive sera using a surface plasmon resonance (SPR) biosensor functionalized with iodinated small molecules. Specifically, an iodixanol-modified dextran sensor chip was constructed to capture sera components with potential ICM reactivity, enabling real-time monitoring of sera–surface binding events. Distinct SPR response patterns were observed between hypersensitive and non-hypersensitive sera, allowing clear group discrimination. Control experiments employing human serum albumin and commercial human IgE confirmed that this differential response cannot be attributed to nonspecific protein adsorption or total IgE binding alone, suggesting the involvement of specific serum factors related to ICM hypersensitivity. The proposed SPR sensing approach provides a robust and reproducible method for serum-level discrimination of ICM hypersensitivity without the need for labeling or complex sample preparation. This work provides a feasible route toward in vitro screening of ICM hypersensitivity and offers a tool for further elucidation of the underlying pathophysiological mechanisms.
20 May 2026 in SSRN Electronic Journal
Type 2 diabetic melitus (T2DM) is characterized by insulin resistance (IR) and dysregualted glucose-lipid metabolism, with hepatic IR representing a critical early pathological event. Current hypoglycemic drugs often have adverse effects and suboptimal efficacy, promoting interest in natural, safe bioactive products with hypoglycemic and lipid-regulatory properties. Turnip (Brassica rapa var. rapa), a traditional food-medicinal homologous crop, contains bioactive components with potential metabolic regulatory effects, yet their systematic isolation and mechanistic elucidation remain insufficient. In this study, we systematically isolated and identified bioactive components from turnip, and found its n-butanol subfraction T-3B exerts potent anti-T2DM effects in db/db mice. T-3B dose-dependently reduces fasting blood glucose (FBG), enhances hepatic and skeletal muscle glucose uptake, and ameliorates dyslipidemia—effects mediated by synergistic activation of the IRβ-IRS1-AKT insulin and AMPK lipid metabolic pathway, which forms a positive feedback loop to modulate systemic metabolism. Six monomeric compounds were isolated from T-3B, among which C2 and C6 exhibited potent hypoglycemic and lipid-regulatory activities. Notably, C2 as the core bioactive component, replicated T-3B’s therapeutic effects in an in vitro hepatocyte model induced by high glucose-high fat (HGF), alleviating lipid metabolism disorders and oxidative stress-induced damage. This study provides a scientific foundation for the medicinal potential of turnip and highlights T-3B, C2 and C6 as promising candidate agents for T2DM therapy.
12 March 2026 in SSRN Electronic Journal
Iodine contrast media (ICM) are extensively applied in diagnostic and interventional imaging, yet hypersensitivity reactions associated with their use remain a major clinical challenge due to their unpredictability and potential severity. Despite the clinical importance, there are currently no serum-based diagnostic methods or mechanistic studies that allow reliable identification of patients with ICM hypersensitivity. In this work, we report a label-free biosensing strategy for discriminating against ICM-hypersensitive sera using a surface plasmon resonance (SPR) biosensor functionalized with iodinated small molecules. Specifically, an iodixanol-modified dextran sensor chip was constructed to capture sera components with potential ICM reactivity, enabling real-time monitoring of sera–surface binding events. Distinct SPR response patterns were observed between hypersensitive and non-hypersensitive sera, allowing clear group discrimination. Control experiments employing human serum albumin and commercial human IgE confirmed that this differential response cannot be attributed to nonspecific protein adsorption or total IgE binding alone, suggesting the involvement of specific serum factors related to ICM hypersensitivity. The proposed SPR sensing approach provides a robust and reproducible method for serum-level discrimination of ICM hypersensitivity without the need for labeling or complex sample preparation. This work provides a feasible route toward in vitro screening of ICM hypersensitivity and offers a tool for further elucidation of the underlying pathophysiological mechanisms.